Point72 Asset Management L.P. Takes $1.40 Million Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 893,762 shares of the biopharmaceutical company’s stock, valued at approximately $1,403,000. Point72 Asset Management L.P. owned 1.36% of Regulus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of RGLS. Creative Planning bought a new stake in shares of Regulus Therapeutics in the third quarter valued at about $26,000. SG Americas Securities LLC bought a new stake in shares of Regulus Therapeutics in the third quarter valued at about $33,000. Rhumbline Advisers bought a new stake in shares of Regulus Therapeutics in the second quarter valued at about $136,000. Tyche Wealth Partners LLC lifted its position in Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 95,694 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in Regulus Therapeutics during the third quarter worth about $204,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Trading Up 4.5 %

Shares of NASDAQ RGLS opened at $1.64 on Wednesday. The company has a market cap of $107.42 million, a price-to-earnings ratio of -1.53 and a beta of 1.61. Regulus Therapeutics Inc. has a 12 month low of $1.08 and a 12 month high of $3.79. The stock has a 50-day moving average price of $1.53 and a two-hundred day moving average price of $1.72.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, sell-side analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on RGLS. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Monday, November 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.